Virginia
Prescription drug spending and prescribing in Virginia, from Medicare Part D and Medicaid, with the life-science companies raising money there and state attorney general health-care antitrust cases. Compare every state.
In 2024, Medicare Part D plans paid $6.1B for prescriptions written in Virginia, the 15th most of 52 states and territories, and 3.3% of its claims were opioids against 3.5% nationally.
- Medicare Part D, 2024: $6.1B
- Medicaid drugs, 2025: $2.5B
- Opioid share of claims: 3.3%
- Life-science raises, 2 years: $505M
How It Prescribes
Medicare Part D, 2024, by the prescriber's state| Share of Part D claims | Virginia | United States | Difference |
|---|---|---|---|
| Opioids | 3.3% | 3.5% | -7% |
| Antibiotics | 4.6% | 4.4% | +4% |
| Antipsychotics | 1.7% | 1.7% | -2% |
Most Distinctive Drugs
Prescribed most out of line with the rest of the country: the drug's share of Virginia's claims against its share nationally| Drug | Against national rate | Claims |
|---|---|---|
| Hydromorphone Hcl | 1.6× | 27,596 |
| Bumetanide | 1.6× | 82,952 |
| Butalb/Acetaminophen/Caffeine | 1.5× | 26,328 |
| Dofetilide | 1.5× | 10,884 |
| Letrozole | 1.5× | 27,448 |
| Ceftriaxone Sodium | 1.4× | 11,178 |
| Cefuroxime Axetil | 1.4× | 36,012 |
| Promethazine Hcl | 1.4× | 39,502 |
| Buprenorphine Hcl/Naloxone Hcl | 1.3× | 53,535 |
| Diclofenac Sodium | 1.3× | 200,899 |
Biggest Medicaid Drugs
What Virginia's Medicaid program paid pharmacies, before rebates; see every drugLife-Science Fundraising
58 Form D raises by companies based in Virginia in the last two years; the 10 largest. See all raises- Quoin Pharmaceuticals, Ltd.$105M · Pharma · Oct 23, 2025
- Rivus Pharmaceuticals, Inc.$57M · Pharma · Jan 16, 2025
- Contraline, Inc.$56M · Biotech · Jun 10, 2026
- Quoin Pharmaceuticals Ltd.$50M · Pharma · Sep 10, 2026
- Phlow Corp.$31M · Pharma · Feb 14, 2025
- ReAlta Life Sciences, Inc.$30M · Biotech · May 21, 2025
- Luminoah, Inc.$25M · Other health care · Nov 6, 2026
- ReAlta Life Sciences, Inc.$25M · Biotech · May 21, 2025
- GENHEALTH, INC.$16M · Biotech · Sep 29, 2026
- Qnovia, Inc.$14M · Pharma · Nov 12, 2024
State Attorney General Health-Care Cases
Antitrust cases Virginia joined, newest first; see every case- Connecticut, et al. v. Sandoz, et al., Case No. 20-cv-3539 (E.D. Pa. June 10, 2020), MDL 2724 (E.D. Pa.)2020 · Pending
- FTC et al. v. Vyera Pharmaceuticals, No. 1:20-cv-00706 (S.D.N.Y. Apr. 19, 2020)2020 · Final judgment
- Connecticut et al. v. Teva Pharmaceuticals USA, Inc. et al., No. 2:19-cv-02407, (E.D. Pa. filed in MDL 05/30/2019)2019 · Pending
- Alabama et al. v. Endo International, No. 3:19-cv-04157 (N.D. Cal. July 19, 2019)2019 · Settled
- California et al. v. Teikoku Seikayu Co.(Lidoderm), No. 3:18-cv-00675 (N.D. Cal. 01/31/18)2018 · Settled
- State of Wisconsin et al. v. Indivior, No. 16-5073 (E.D. Pa. Sept. 22,2016)2016 · Pending
- Connecticut et al. v. Teva Pharmaceuticals et al. Civ. Action No. (D.Conn. Dec. 15, 2016)2016 · Pending
- New York et al. v. Cephalon, No. 2:16-cv-04234 (E.D. Pa. Aug. 4, 2016)2016 · Settled
- Maryland v. SmithKline Beecham Corp., No. 2:06-cv-01298-JP (E.D.Pa Mar. 27, 2006)2006 · Settled
- State of Colorado et al v. Warner Chilcott, 1:05-cv-02182 (D.D.C.2005)2005 · Settled
Other States
Alabama · Alaska · Arizona · Arkansas · California · Colorado · Connecticut · Delaware · District of Columbia · Florida · Georgia · Hawaii · Idaho · Illinois · Indiana · Iowa · Kansas · Kentucky · Louisiana · Maine · Maryland · Massachusetts · Michigan · Minnesota · Mississippi · Missouri · Montana · Nebraska · Nevada · New Hampshire · New Jersey · New Mexico · New York · North Carolina · North Dakota · Ohio · Oklahoma · Oregon · Pennsylvania · Puerto Rico · Rhode Island · South Carolina · South Dakota · Tennessee · Texas · Utah · Vermont · Washington · West Virginia · Wisconsin · Wyoming
Part D is by the prescriber's state, Medicaid by the paying state program, and Form D by the issuer's stated address. Amounts are before manufacturer rebates. Refreshed weekly. CMS Medicare Part D Prescribers by Geography; CMS State Drug Utilization Data; SEC Form D; NAAG